Send this to a friend

Hologic subsidiary to lose $15M after FDA warns of device claims

Marlborough medical device maker Hologic is expecting revenues from subsidiary Cynosure to be about $15 million less after it halted sales of a device due to a government warning.
Westford-based Cynosure, an aesthetic laser treatment firm, said Wednesday the loss is due to lost sales of Tempsure Vitalia in the fourth quarter, refunds and rebates associated with prior sales of the device, unused devices and reduced sales of the MonaLisa Touch.

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media